Company Watch

Dabur OncQuest forays into Nepal

Our News Bureau - Mumbai

In a bid to spread its network, Dabur OncQuest has announced its foray into Kathmandu, Nepal. Through this, the patients in Nepal will now have access to all the technically advanced and cost-effective diagnostic tests being offered by Dabur OncQuest in India. Commenting on this development, Aditya Burman, General Manager, Dabur Pharma, said, "OncQuest has excelled and pioneered many cost-effective cancer tests, with its in-house R&D laboratory; Imanitib Drug Resistance Mutation Analysis (IRMA) being one of the tests. Cancer patients in Nepal have to bear high costs of the tests despite it being offered by OncQuest in India at almost half of the US prices. Understanding the high cost and the need gap of tests available in Nepal we decided to reach out to the patients by extending our advanced and economical services. We have always believed and stood by the fact that world class patient management is the prime need for our business operations." Elaborating on the same lines, Vivek Trikha, Head Diagnostics, Dabur OncQuest said, "Foreseeing huge potential in Nepal, we did a pilot run and diagnosed samples of over 200 patients leading to business of more than Rs 15 lakh. We are pleased to announce our full-fledged services in Nepal through our first commercial collection centre in Kathmandu." The company is also planning to develop two more collection centres at Bharatpur and Chitwann."

OncQuest works on a 'Hub and Spoke' model. All specimens across board are brought into the 'Gold Standard' NABL accredited laboratory at New Delhi, which are tested. The reports are delivered within set turn around time, in leak proof packaging for superior specimen collection, storage and temperature controlled corrugated boxes